A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants

Summary

1. Learn about the safety and tolerability of CK-3828136 after a single dose and multiple doses in healthy subjects. 2. Find out how much CK-3828136 is in the blood after a single dose and multiple doses. 3. Determine the effect different doses of CK-3828136 on the pumping function of the heart.

Timeline

Start

2022-12-06

Primary completion

2023-08-08

Completion

2023-08-08

Outcome

Met primary endpoint

Stopped (Business): “Terminated early per sponsor decision.”

release “CK-3828136 (CK-136, cardiac troponin activator) Completed analyses of the Phase 1 study of CK-136, which met its primary objective” cytokinetics.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NELUTROCTIV	Small molecule	—	—

Indications

No indication recorded.